To include your compound in the COVID-19 Resource Center, submit it here.

ethris and AZ partner to develop respiratory mRNA therapies

ethris GmbH (Martinsried, Germany) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit to develop mRNA therapies for respiratory diseases using ethris' stabilized non-immunogenic messenger RNA (SNIM-RNA) technology. ethris

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE